- Home
- TIL vs CRBP Comparison
TIL vs CRBP Comparison
Compare TIL & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- CRBP
- Stock Information
- Founded
- TIL 2018
- CRBP 2009
- Country
- TIL United States
- CRBP United States
- Employees
- TIL N/A
- CRBP N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- TIL Health Care
- CRBP Health Care
- Exchange
- TIL Nasdaq
- CRBP Nasdaq
- Market Cap
- TIL 134.5M
- CRBP 143.7M
- IPO Year
- TIL 2021
- CRBP N/A
- Fundamental
- Price
- TIL $20.97
- CRBP $11.96
- Analyst Decision
- TIL Strong Buy
- CRBP Strong Buy
- Analyst Count
- TIL 4
- CRBP 8
- Target Price
- TIL $114.00
- CRBP $62.00
- AVG Volume (30 Days)
- TIL 103.6K
- CRBP 256.8K
- Earning Date
- TIL 11-13-2024
- CRBP 03-11-2025
- Dividend Yield
- TIL N/A
- CRBP N/A
- EPS Growth
- TIL N/A
- CRBP N/A
- EPS
- TIL N/A
- CRBP N/A
- Revenue
- TIL N/A
- CRBP N/A
- Revenue This Year
- TIL N/A
- CRBP N/A
- Revenue Next Year
- TIL $2.65
- CRBP N/A
- P/E Ratio
- TIL N/A
- CRBP N/A
- Revenue Growth
- TIL N/A
- CRBP N/A
- 52 Week Low
- TIL $9.20
- CRBP $6.63
- 52 Week High
- TIL $92.00
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- TIL 46.36
- CRBP 46.35
- Support Level
- TIL $18.56
- CRBP $11.02
- Resistance Level
- TIL $22.00
- CRBP $13.28
- Average True Range (ATR)
- TIL 1.98
- CRBP 0.67
- MACD
- TIL 0.36
- CRBP 0.24
- Stochastic Oscillator
- TIL 28.05
- CRBP 87.07
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.